A review of current literature in JAMA Internal Medicine on amyloid-beta PET imaging for Alzheimer's disease (AD) has found insufficient evidence that it leads to better clinical outcomes.
"The available evidence on [amyloid-beta] PET has many limitations beyond the sparse number of studies," wrote Steven D. Pearson, M.D., and colleagues from the Institute for Clinical and Economic Review in Boston. "Nearly all the studies have evaluated diagnostic performance, not whether test results improve clinical management or patient outcomes. Many potential benefits and harms of the imaging have not been evaluated."
The Center for Medicare & Medicaid Services recently released a coverage decision denying coverage for amyloid-beta ET scans in routine clinical care. Article